The President of the Pharmaceutical Association of Nigeria (PSN), Pharmacist Ahmed Yakassai, has revealed that the National Institute for Pharmaceutical Research and Development (NIPRD), will in the next couple of days sign a Memorandum of Understanding (MoU) with May and Baker for commercial production of NIPRSAND.
Yakassai, who revealed this yesterday at the commissioning of a monument donated by PSN to NIPRD in Abuja, said NIPRSAND is a cure for sickle cell anemia, with huge market in the West African sub-Region.
He noted that poor funding of the institute has led to continued under performance of the NIPRD and redundancy of world class equipment at the facility.
The President of PSN said: “PSN has been engaging, and having strategic meetings with May and Baker among others, towards ensuring that NIPRD begins manufacturing of products in commercial quantities.
“Negotiations are underway with world class pharmaceutical companies, to partner with the National Institute for Pharmaceutical Research and Development (NIPRD), to ensure optimal operation of the institute.”
Speaking, the Director General of NIPRD, Prof Karniyus Garmaniel, noted that since drawing a proposition, which led to the establishment of the institute, PSN has continued to work for the progress and success of the institute.
He said: “PSN is brokering partnership between NIPRD and other organisations and individuals.
“PSN has also intervened in encouraging government to pay attention to NIPRD, and have contributed through direct funding into the institute for specific projects.”